A detailed history of Hsbc Holdings PLC transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 58,530 shares of PSTX stock, worth $552,523. This represents 0.0% of its overall portfolio holdings.

Number of Shares
58,530
Previous 56,616 3.38%
Holding current value
$552,523
Previous $165,000 1.21%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.7 - $4.04 $5,167 - $7,732
1,914 Added 3.38%
58,530 $167,000
Q2 2024

Aug 12, 2024

SELL
$2.0 - $3.46 $238 - $411
-119 Reduced 0.21%
56,616 $165,000
Q1 2024

May 15, 2024

BUY
$2.76 - $4.13 $21,370 - $31,978
7,743 Added 15.8%
56,735 $180,000
Q4 2023

Feb 12, 2024

BUY
$1.83 - $3.51 $100 - $193
55 Added 0.11%
48,992 $164,000
Q3 2023

Nov 13, 2023

BUY
$1.62 - $2.79 $79,277 - $136,534
48,937 New
48,937 $116,000

Others Institutions Holding PSTX

About Poseida Therapeutics, Inc.


  • Ticker PSTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 85,775,600
  • Market Cap $810M
  • Description
  • Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...
More about PSTX
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.